The first proofs of activity of selpercatinib towards two patients have also been described: one patient with RET-mutated (M918T) medullary thyroid carcinoma refractory to multi-TKIs (sorafenib, vandetanib, and cabozantinib) and another patient with RET fusion + NSCLC progressing on chemotherapy, erlotinib, nivolumab, and alectinib [73]. Here, RET is linked to medullary thyroid gland carcinoma.